Titlebook: Lymphohaematopoietic Growth Factors in Cancer Therapy II; Roland Mertelsmann Conference proceedings 1992 Springer-Verlag Berlin Heidelberg

occurrence

Clinical Trials with Local Administration of Lymphopoietic Growth Factorsof an immune response by acting as the elements of a cell-cell communication code. Moreover, the experimental addition of ILs amplifies many immune reaction mechanisms both . and . [1]. Efforts have, therefore, been made to use ILs to modulate immune responses. This approach has been rendered easier

熱烈的歡迎

Clinical Trials with Interleukin-2. The Rome Experienceect included a series of experimental and clinical studies, carried out at the Department of Medical Oncology I of the Regina Elena National Cancer Institute of Rome, partially in collaboration with the Laboratory of Haematology and Oncology of the Italian National Institute of Health and the Depart

blight

召集

獨裁政府

承認

Federica Cavallo,Mirella Giovarelli,Francesco Novelli,Guido Forni

捏造

Lymphohaematopoietic Growth Factors in Cancer Therapy II

CHAFE

臭名昭著

發(fā)現(xiàn)

Natural Killer Cells and Interleukin-2-Activated Killer Cells even some normal tissue cells [6]. Such IL-2-activated effector cells have been referred to operationally as lymphokine-activated killer (LAK) cells [7]. In studies using blood from normal human donors, the phenomena of NK and LAK activities were shown to be closely related because NK cells are the